Active Recombinant Human CD40 Protein, His & Avi-tagged, Biotinylated

• Cat.No.: CD40-2222H
• Product Overview: Biotinylated Recombinant Human CD40 Protein (Glu 21 - Arg 193) (AAH12419.1), fused with an Avi tag at the C-terminus, followed by a polyhistidine tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: His & Avi
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
• Bio-activity: Immobilized Biotinylated Human CD40 Protein, Avitag,His Tag at 1 μg/mL (100 μL/well) on Recombinant Streptavidin precoated (0.5μg/well) plate, can bind Human CD40 Ligand, Fc Tag with a linear range of 0.2-2 ng/mL.
• Molecular Mass: The protein has a calculated MW of 21.8 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Protein Length: Glu 21 - Arg 193
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
  >90% as determined by SEC-MALS.
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
  Please avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20 centigrade to -70 centigrade for 12 months in lyophilized state;
  -70 centigrade for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: CD40 CD40 molecule, TNF receptor superfamily member 5 [ Homo sapiens ]
• Official Symbol: CD40
• Synonyms: CD40; CD40 molecule, TNF receptor superfamily member 5; TNFRSF5, tumor necrosis factor receptor superfamily, member 5; tumor necrosis factor receptor superfamily member 5; Bp50; p50; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; B-cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); tumor necrosis factor receptor superfamily, member 5; nerve growth factor receptor-related B-lymphocyte activation molecule; CDW40; TNFRSF5; MGC9013
• Gene ID: 958
• mRNA Refseq: NM_001250
• Protein Refseq: NP_001241
• MIM: 109535
• UniProt ID: P25942

Reviews

10/28/2021

Its utilization in this technique has allowed for precise visualization and determination of protein structures with remarkable clarity and resolution.

08/11/2021

The reliable and high-quality results obtained using CD40 protein make it an excellent choice for researchers studying protein structures.

10/07/2018

CD40 protein has proved to be an invaluable tool in protein electron microscopy structure analysis.

Q&As

Can CD40-targeted therapies be used in the treatment of infectious diseases?

CD40 agonists have the potential to enhance immune responses against infectious agents, but their clinical use in this context is an area of ongoing research.

Are there any approved drugs targeting CD40 for clinical use?

As of my knowledge cutoff date in January 2022, there were no FDA-approved drugs specifically targeting CD40. However, clinical trials were ongoing for CD40-targeted therapies.

Can CD40-targeted therapies be used in combination with other cancer treatments?

Yes, CD40-targeted therapies are often investigated in combination with other treatments like checkpoint inhibitors or chemotherapy to enhance their effectiveness.

What are the potential side effects of CD40-targeted therapies in cancer treatment?

Side effects may include flu-like symptoms, cytokine release syndrome, and immune-related adverse events, which can be managed with supportive care and close monitoring.

Are there ongoing clinical trials exploring CD40-targeted therapies for atherosclerosis?

Research on CD40-targeted therapies for atherosclerosis is still in the experimental stages and not yet in advanced clinical trials.